Trial Profile
Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2021
Price :
$35
*
At a glance
- Drugs Nabilone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms NMS-Nab
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 05 Aug 2020 Primary endpoint (Change from baseline to Week 4/Termination Visit in the MDS-UPDRS Part I (non-motor Expriences of daily living; nmEDL) has been met according to the results published in the Annals of Neurology
- 05 Aug 2020 Results published in the Annals of Neurology